XNCR — Xencor Inc
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1326732 ·
Last close
$34.50
Market Cap
$2.59B
52W High
$40.60
52W Low
$10.38
ADV30
1,677,504
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 116,520,000 | — | 22,864,000 | 39,436,000 | 770,505,000 | 59,622,000 | 210,070,000 |
| Jun 2026 | 51,221,000 | — | -37,068,000 | -21,729,000 | 724,960,000 | 44,663,000 | 221,732,000 |
| Mar 2026 | 4,516,000 | — | -77,862,000 | -128,916,000 | 736,846,000 | 14,170,000 | 221,213,000 |
| Dec 2025 | 28,237,000 | — | -53,628,000 | -6,653,000 | 875,495,000 | 54,073,000 | 239,908,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-172,355,000
Investing CF
$190,298,000
Financing CF
$18,293,000
CapEx
$-4,092,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.59
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-907,168,000
Inventory
—
Receivables
$64,837,000
ST Investments
$345,457,000
EBIT TTM
$-92,040,000
Pretax Income TTM
$-115,560,000
Interest Exp TTM
$23,520,000
Analysts
12
Yahoo Snapshot (yfinance, live)
Total Revenue
$200,494,000
EBITDA
$-135,872,000
Free Cash Flow
$-96,220,752
Enterprise Value
$2,437,816,832
Total Cash
$405,079,008
Total Debt
$160,227,008
Shares Out
75,039,689
Trailing EPS
$-1.56
Book Value
$7.50
ROE
-19.9%
ROA
-11.1%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 125,576,000 | -177,502,000 | -91,923,000 | 875,495,000 | 239,908,000 | 635,587,000 | -135,117,000 |
| Dec 2024 | 110,493,000 | -178,408,000 | -232,618,000 | 951,945,000 | 277,919,000 | 677,611,000 | -202,188,000 |
| Dec 2023 | 174,615,000 | -132,362,000 | -133,133,000 | 965,135,000 | 303,048,000 | 661,750,000 | -77,926,000 |
| Dec 2022 | 164,579,000 | -82,473,000 | -55,181,000 | 846,266,000 | 118,770,000 | 727,496,000 | 24,485,000 |
TTM Snapshot
Revenues TTM
$104,973,000
NetIncome TTM
$-163,325,000
OpCashFlow TTM
—
Assets (Latest)
$724,960,000
Forward EPS
$-3.54
Max Pain — expiry 2027-02-19 (volume-derived — Yahoo OI feed degraded)
max pain strike: $22.50 · spot: $34.39 · call volume: 274 · put volume: 27
Expected Move to 2027-02-19:
±$11.00
(31.99%) —
implied range
$23.39 –
$45.39
· ATM straddle on $35.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MBX | MBX Biosciences, Inc. | $2.64B | $53.10 | — |
| IDYA | IDEAYA Biosciences, Inc. | $2.65B | $27.40 | — |
| HCM | HUTCHMED (China) Ltd | $2.50B | $14.40 | — |
| RCUS | Arcus Biosciences, Inc. | $2.36B | $16.39 | — |
| NAMS | NewAmsterdam Pharma Co N.V. | $2.33B | $19.39 | — |
News headlines (Yahoo Finance, 1h cache)
Early Arthritis Data Could Be A Big Test For Xencor Stock (XNCR)
2026-11-12 09:11 · Yahoo
Xencor (XNCR) Stock Trades At A Premium To Its Sales
2026-11-05 07:19 · Yahoo
Xencor: Q3 Earnings Snapshot
2026-11-04 21:26 · Yahoo
Xencor Reports Third Quarter 2026 Financial Results
2026-11-04 21:01 · Yahoo
Xencor Sees Upside Potential After 'Exciting' Kidney Cancer Trial Data, RBC Capital Markets Says
2026-10-27 15:51 · Yahoo
Xencor (XNCR) Is Up 15.8% What's Changed After Kidney Cancer Trial Update
2026-10-26 22:21 · Yahoo
Xencor Catapults On 'Unprecedented,' 'Profound' Cancer Data
2026-10-26 20:13 · Yahoo
Xencor Picks Phase 3 Dose After XmAb819 Shows 45.5% Response Rate in Kidney Cancer
2026-10-26 19:02 · Yahoo
Xencor Soars 31% on Kidney Cancer Trial Data Showing “Impressive Antitumor Activity”
2026-10-26 18:55 · Yahoo
Xencor shares jump as kidney cancer drug data support Phase 3 plans
2026-10-26 16:08 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.